Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selnoflast (IZD334) in Healthy Volunteers and CAPS Patients
NCT04086602Phase 1Completed
- Sponsor
- Inflazome
- Start
- Sep 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selnoflast in Cryopyrin-associated periodic syndromes (CAPS) (5 arms), sponsored by Inflazome. Primary endpoints: Incidence of treatment emergent adverse events [Safety and Tolerability], Peak plasma concentration (Cmax) single dose and 3 more. Started Sep 2019; status: completed.
02
Drugs
selnoflast
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT04086602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04086602.